• Decoy Therapeutics named Brad L. Pentelute as chair of its scientific advisory board on May 26, 2026.
• Pentelute is a co-founder of Decoy. He has served as a technology adviser since inception.
• He is a professor of chemistry at MIT. His work focuses on peptide synthesis, protein engineering, rapid flow synthesis.
• He succeeds Shahin Gharakhanian as SAB chair. Gharakhanian will continue working with the company.
• Pentelute will help guide the IMP3ACT platform, supporting development of designable multi-antivirals toward clinical-stage progress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605260815PR_NEWS_USPR_____NE67344) on May 26, 2026, and is solely responsible for the information contained therein.